Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom
Novo Nordisk Investigational Site, Tacoma, Washington, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
GSK Investigational Site, Nijmegen, Netherlands
Yale School of Medicine, New Haven, Connecticut, United States
VU University Medical Center, Amsterdam, Netherlands
Clinical research Center Nijmegen, Nijmegen, Netherlands
GSK Investigational Site, Montreal, Quebec, Canada
GSK Investigational Site, Worle, Weston-Super-Mare, United Kingdom
AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece
Aristotle University of Thessaloniki, Thessaloniki, Greece
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.